News
ONCO
0.9765
-0.34%
-0.0033
Onconetix says Realbotix acquisition closing expected in H2 2026
PUBT · 3d ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 3d ago
Weekly Report: what happened at ONCO last week (0615-0619)?
Weekly Report · 5d ago
Oncopeptides Announces First Patient Enrollment In Clinical "Window-Of-Opportunity" Study Evaluating Proprietary Peptide Drug Conjugate Platform In Glioblastoma
Benzinga · 06/17 11:53
Weekly Report: what happened at ONCO last week (0608-0612)?
Weekly Report · 06/15 10:18
Onconetix files to sell 100M shares of common stock for holders
TipRanks · 06/09 10:06
ONCONETIX - REGISTERS UP TO 100 MLN SHARES FOR RESALE BY KEYSTONE CAPITAL PARTNERS - SEC FILING
Reuters · 06/09 10:01
Weekly Report: what happened at ONCO last week (0601-0605)?
Weekly Report · 06/08 10:14
Weekly Report: what happened at ONCO last week (0525-0529)?
Weekly Report · 06/01 10:18
Realbotix swings to Q2 FY26 profit of USD 442,375; revenue falls to USD 225,000
PUBT · 05/29 11:30
Weekly Report: what happened at ONCO last week (0518-0522)?
Weekly Report · 05/25 10:21
Onconetix Inc trading halted, news pending
TipRanks · 05/20 23:50
Onconetix Implements 1-for-10 Reverse Stock Split For Nasdaq Compliance; Stock Down
NASDAQ · 05/20 07:49
Onconetix Sets 1-for-10 Reverse Stock Split Effective
TipRanks · 05/19 20:52
BUZZ-U.S. STOCKS ON THE MOVE- Hims & Hers Health, Driven Brands, Onto Innovation
Reuters · 05/19 17:42
Gold Falls 1%; Amer Sports Earnings Top Views
Benzinga · 05/19 16:29
BUZZ-U.S. STOCKS ON THE MOVE-T1 Energy, Home Depot, X-Energy     
Reuters · 05/19 15:48
Dow Falls Over 100 Points; Home Depot Posts Upbeat Earnings
Benzinga · 05/19 14:06
UPDATED: Onconetix Announces 1-For-10 Reverse Stock Split, Effective May 21, 2026
Benzinga · 05/19 12:43
Onconetix to implement 1-for-10 reverse stock split May 21
PUBT · 05/19 12:07
More
Webull provides a variety of real-time ONCO stock news. You can receive the latest news about Onconetix through multiple platforms. This information may help you make smarter investment decisions.
About ONCO
Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.